Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Pancreatic cancer is a lethal disease, with fewer than 7% of patients surviving beyond 5
years following diagnosis. Immune responses are known to influence tumour progression …

The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal
growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Purpose: Current clinical classification of pancreatic ductal adenocarcinoma (PDAC) is
unable to predict prognosis or response to chemo-or immunotherapy and does not take into …

Background Accumulating evidence suggests that circular RNAs (circRNAs) are important
participants in cancer progression. However, the biological processes and underlying …

Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Lung cancer is treated with many conventional therapies, such as surgery, radiation, and
chemotherapy. However, these therapies have multiple undesirable side effects. To bypass …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …